Clopidogrel enhancement of rt-PA thrombolysis in a thrombo-embolic model of cerebral ischemia in rats

Fibrinolysis and Proteolysis

Volumn 12, Issue 2, 1998, Pages 97-105

  Hoffman, P ^a   Pottier, P ^a   Sainte Marie, M ^a   Bernat, A ^a   Herbert, J M ^a  

^a SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ARTIFICIAL EMBOLISM; BLOOD CLOT LYSIS; BRAIN ISCHEMIA; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; MIDDLE CEREBRAL ARTERY; NONHUMAN; PRIORITY JOURNAL; RAT; RECANALIZATION; SECONDARY PREVENTION; STROKE; THROMBOCYTE AGGREGATION; THROMBOEMBOLISM;

EID: 0031800729     PISSN: 13690191     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-9499(98)80382-2     Document Type: Article

References (38)

1. Collen D, Stump D, Gold H. Thrombolytic therapy. Ann Rev Med 1988; 39: 405-420.
2. Fears R. Biochemical pharmacology and therapeutic aspects of thrombolytic agents. Pharmacol Rev 1990; 32: 201-222.
3. Goldhaber S Z. Thrombolysis for pulmonary embolism. Prog Cardiovasc Dis 1991; 34: 113-134.
4. Barr H, Lancashire M J, Torrie R P, Galland R B. Intra-arterial thrombolytic therapy in the management of acute and chronic limb ischemia. Br J Surg 1991; 78: 284-287.
5. Hommel M, Boissel J P, Cornu C, et al. Termination of trial of streptokinase in severe acute ischaemic stroke. Lancet 1995; 345: 57
6. Boysen G, Overgaard K. Thrombolysis in ischaemic stroke how far from a clinical breakthrough? J Intern Med 1995; 237: 95-103.
7. Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. JAMA 1995; 274: 1017-1025.
8. The National Institute of Neurologic Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333: 1581-1587.
9. Sloan M A. Thrombolysis and stroke. Past and future. Arch Neurol 1987; 44: 748-768.
10. International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet 1997; 349: 1569-1581.
11. Antiplatelet Trialists' Collaboration. Collaborative overview of randomized trials of antiplatelet therapy, I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994; 308: 81-106.
12. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-1339.
13. Sasaki Y, Ishii I, Giddings J C, Yamamoto J. Protective effects of ticlopidine and aspirin, administered alone and in combination, on thrombus formation in rat cerebral vessels. Haemostasis 1996; 26: 150-156.
14. Fujimoto T, Suzuki H, Tanoue K, Fukushima Y, Yamazaki H. Autoradiographic observation of platelets in cerebrovascular injuries induced by arachidonic acid and its prevention by ticlopidine. Thromb Haemost 1988; 60: 319-323.
15. Umemura K, Ishihara H, Nakashima M. Antiplatelet effects of clopidogrel in rat middle cerebral artery thrombosis model. Thromb Res 1995; 80: 209-216.
16. Umemura K, Kawai H, Ishihara H, Nakashima M. Inhibitory effect of clopidogrel, vapiprost and argatroban on the middle cerebral artery thrombosis in the rat. Jpn J Pharmacol 1995; 67: 253-258.
17. Third International study of infarct survival collaborative group ISIS-3. A randomized comparison of streptokinase vs issue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41 299 cases suspected acute myocardial infarction. Lancet 1992; 339: 753-770.
18. Overgaard K, Sereghy T, Pedersen H, Boysen G. Dose-response of rt-PA and its combination with aspirin in a rat embolic stroke model. Clin Neurose Neuropath-NeuroReport 1992; 3: 925-928.
19. Bednar M M, Raymond-Russel S J, Booth C L, Gross C E. Combination tissue plasminogen activator and ticlopidine therapy in a rabbit model of acute thromboembolic stroke. Neurol Res 1996; 18: 45-48.
20. Hoffmann P, Sainte Marie M, Bernat A, et al. Stroke outcome determination with a prefabricated fibrin-rich thrombus in a thromboembolic rat MCA occlusion model. Cerebrovasc Dis 1997; 7(suppl 4): 79.
21. Herbert J M, Fréhel D, Vallée E, et al. Clopidogrel, a novel antiplatelet and antithrombotic agent. Cardiovasc Drug Rev 1993; 11: 180-198.
22. Bederson J B, Pitts L H, Tsuji M, Nishimura M C, Davis R L, Bartkowski H. Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination. Stroke 1986, 17: 472-476.
23. Herbert J M, Hérault J P, Bernat A, et al. Biochemical and pharmacological properties of SANORG 32701. Comparison with the 'Synthetic pentasaccharide' (SR 90107/ORG 31540) and standard heparin. Circ Res 1996; 79: 590-600.
24. Bernat A, Hoffmann P, Sainte-Marie M, Herbert J M. The synthetic pentasaccharide SR 90107A/Org 31540 enhances tissue-type plasminogen activator-induced thrombolysis in rabbits. Fibrinolysis 1996; 10: 151-157.
25. Yao S K, Ober J C, Ferguson J J, et al. Clopidogrel is more effective than aspirin as adjuvant treatment to prevent reocclusion after thrombolysis. Am J Physiol 1994; 267 (Heart Circ Physiol 36): H488-H493.
26. Defreyn G, Gachet C, Savi P, Driot F, Cazenave J P, Maffrand J P. Ticlopidine and clopidogrel (SR 25990C) selectively neutralize ADP inhibition of PGE1-activated platelet adenylate cyclase in rats and rabbits. Thromb Haemost 1991; 65: 186-190.
27. Hallenbeck J M, Dutka A J. Background review and current concepts of reperfusion injury. Arch Neurol 1990; 47: 1245-1254.
28. Siesjö B K, Zhao Qi, Pahlmark K, Siesjö P, Katsura K-i, Folbergrová J. Glutamate, calcium, and free radicals as mediators of ischemic brain damage. Ann Thorac Surg 1995; 59: 1316-1320.
29. Koudstaal P J, Stibbe J, Vermeulen M. Fatal ischaemic brain oedema after early thrombolysis with tissue plasminogen activator in acute stroke. Br Med J 1988; 297: 1571-1574.
30. Koistinaho J, Hökfelt T. Altered gene expression in brain ischemia. NeuroReport 1997; 8: i-viii.
31. Garcia J, Liu K, Yoshida Y, et al. Influx of leukocytes and platelets in an evolving brain infarct. Am J Pathol 1994; 144: 188-199.
32. Del Zoppo G J, Schmid-Schönbein G W, Mori E, et al. Polymorphonuclear leukocytes occlude capillaries following middle cerebral artery occlusion and reperfusion in baboons. Stroke 1991; 22: 1276-1283.
33. Hayward N J, Elliott P J, Sawyer S D, Bronson R T, Bartus R T. Lack of evidence for neutrophil participation during infarct formation following focal cerebral ischemia in the rat. Exp Neurol 1996; 139: 188-202.
34. Grotta J. A glimpse to the future: multitherapy trials. Cerebrovasc Dis 1995; 5 (suppl 1): 27-30.
35. Meden P, Overgaard K, Pedersen H, Boysen G. Effect of early treatment with tirilazad (U74006F) combined with delayed thrombolytic therapy in rat embolic stroke. Cerebrovasc Dis 1996; 6: 141-148.
36. Sereghy T, Overgaard K, Boysen G. Neuroprotection by excitatory amino acid antagonist augments the benefit of thrombolysis in embolic stroke in rats. Stroke 1993; 24: 1702-1708.
37. Zivin J, Mazzarella V. Tissue plasminogen activator plus glutamate antagonist improves outcome after embolic stroke. Arch Neurol 1991; 48: 1235-1238.
38. Thomas G R, Thibodeaux H, Errett C J, Bednar M M, Gross C E, Bennett W F. Intravenous aspirin causes a paradoxical attenuation of cerebrovascular thrombolysis. Stroke 1995; 26: 1039-1046.